Data Sheet (Cat.No.T15550)



IDH-305

Chemical Properties


CAS No.: 1628805-46-8

Formula: C23H22F4N6O2

Molecular Weight: 490.45

Appearance: no data available

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year



Biological Description

Description	IDH-305 is an orally available, mutation-selective, and brain-penetrant IDH1 inhibitor targeting the IDH1 (R132) mutation. IDH-305 is 200-fold more selective for mutant IDH1 isoforms than wild type with IC50s of 27 nM,28 nM and 6.14 nM for IDH1R132H, IDH1R132C and IDH1WT, respectively.
Targets(IC50)	Dehydrogenase
In vitro	IDH-305 suppresses HCT116-IDH1R132H /- cells (IC50 of 24 nM)[1].
In vivo	P.o. administration of 30-300 mg/kg IDH-305 twice daily for 21 days suppresses 2-HG production and 2-HG-dependent tumor growth of an IDH1 mutant PDX melanoma model [1].

Solubility Information

Solubility	DMSO: 100 mg/mL (203.90 mM)
(0)	(< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg	
1 mM	2.0389 mL	10.1947 mL	20.3894 mL	
5 mM	0.4078 mL	2.0389 mL	4.0779 mL	
10 mM	0.2039 mL	1.0195 mL	2.0389 mL	
50 mM	0.0408 mL	0.2039 mL	0.4078 mL	

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Page 1 of 2 www.targetmol.com

Reference

Cho YS, et al. Discovery and Evaluation of Clinical Candidate IDH305, a Brain Penetrant Mutant IDH1 Inhibitor. ACS Med Chem Lett. 2017 Sep 18;8(10):1116-1121.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only· Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:36 Washington Street, Wellesley Hills, MA 02481

Page 2 of 2 www.targetmol.com